Compare Amylx Pharmaceuticals Inc (AMLX) vs American Express Co (AXP) Price & Performance

AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.

The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.

American Express (AXP) trades at $350.58, up 1.11% today, with a bullish technical signal and strong fundamentals. Revenue grew to $72.23B in 2025, with net income of $10.83B and a 15.13% margin. Recent earnings beat expectations in Q1 2026, and the company is expanding its premium cardholder perks and AI initiatives, including a new NFL partnership and headquarters development at 2 World Trade Center.

The outlook is positive with a consensus price target of $375.27, implying 7% upside. Risks include economic sensitivity and competitive pressures, but robust consumer spending and innovation in digital payments support growth. Analyst sentiment is mixed with 38.6% buy ratings, highlighting potential for steady gains amid macroeconomic uncertainty.